aluates Reports

$ 0.0

Automative

Global PD-1/PD-L1 Checkpoint Inhibitors Market Research Report 2026

Published Date: 2026-02-09

Report Code: QYRE-Auto-0L18747

Global PD 1 PD L1 Checkpoint Inhibitors Market Research Report 2024

BUY CHAPTERS

Global PD-1/PD-L1 Checkpoint Inhibitors Market Research Report 2026

Code: QYRE-Auto-0L18747

Report

2026-02-09

Pages:110

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Bristol–Myers Squibb

Merck

Regeneron Pharmaceuticals

Roche

Pfizer Inc

Astrazeneca plc

Hengrui Pharmaceuticals

Junshi Biosciences

Innovent

PD-1/PD-L1 Checkpoint Inhibitors Market Size

The global PD-1/PD-L1 Checkpoint Inhibitors market was valued at US$ 58150 million in 2025 and is anticipated to reach US$ 121030 million by 2032, at a CAGR of 11.2% from 2026 to 2032.

PD-1/PD-L1 Checkpoint Inhibitors Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on PD-1/PD-L1 Checkpoint Inhibitors competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

PD-1/PD-L1 checkpoint inhibitors are a class of immuno-oncology therapies designed to block the immune-suppressive signaling pathway that tumors exploit to deactivate T-cell–mediated antitumor immunity. These agents address the unmet need of patients whose tumors are resistant or poorly responsive to conventional chemotherapy and targeted therapies. The concept emerged as researchers uncovered how malignant cells overexpress PD-L1 or engage PD-1 on T cells to evade immune surveillance; the development of monoclonal antibodies capable of binding and blocking these proteins led to a therapeutic breakthrough, with the first approvals in 2014 reshaping cancer treatment worldwide. Their development and manufacturing rely on an upstream supply chain that includes cell line development materials, recombinant protein expression systems, culture media, buffers, filtration consumables, bioreactors, and aseptic filling components. This also covers nucleic acid materials for antibody engineering, analytical reagents, and instrumentation essential for quality control, forming a comprehensive upstream ecosystem that ensures product consistency, safety, and clinical performance. In 2024, global sales of PD-1/PD-L1 checkpoint inhibitors reached 28.64 million vials, with an average price of USD 1,850 per vial, and corporate gross profit margins ranging between 60% and 70%.

From a market perspective, the PD-1/PD-L1 inhibitor landscape has transitioned from a narrow set of indications to a broad, heterogeneous adoption across cancer types and treatment lines, accompanied by an increasingly crowded supplier ecosystem. Market dynamics are shaped not only by competing products but also by a growing ancillary industry of diagnostic developers, contract manufacturers and service providers that support clinical translation and commercialization. Regional differences in clinical guidelines, payer policies and healthcare infrastructure further lead to heterogeneous uptake patterns, even as overall clinical familiarity and guideline inclusion continue to strengthen usage.

Looking ahead, two complementary trends will dominate: precision immunotherapy and rational combinations. Precision approaches that integrate tumor genomics, immune microenvironment profiling and predictive biomarkers will refine patient selection and improve benefit–risk ratios, while combination regimens aim to broaden responder populations and delay or overcome resistance. Concurrently, platform innovations — such as engineered antibodies, bispecific constructs, long-acting formats and localized delivery systems — will diversify the therapeutic toolbox and open niche application opportunities.

Key growth drivers include persistent unmet clinical needs, robust R&D funding, and evolving regulatory frameworks that increasingly accommodate breakthrough immunotherapies; clinician experience and patient advocacy also accelerate adoption. Major constraints remain: intrinsic and acquired resistance in certain tumor types, uneven access driven by cost and reimbursement variability, and the high technical and capital barriers of biologics development and manufacturing. The interplay among scientific advances, payer decisions and real-world evidence generation will determine how rapidly and equitably these therapies diffuse into broader oncology practice.

This report delivers a comprehensive overview of the global PD-1/PD-L1 Checkpoint Inhibitors market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding PD-1/PD-L1 Checkpoint Inhibitors. The PD-1/PD-L1 Checkpoint Inhibitors market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global PD-1/PD-L1 Checkpoint Inhibitors market comprehensively. Regional market sizes by Type, by Application, by Product Name, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist PD-1/PD-L1 Checkpoint Inhibitors manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of PD-1/PD-L1 Checkpoint Inhibitors Market Report

Report Metric	Details
Report Name	PD-1/PD-L1 Checkpoint Inhibitors Market
Accounted market size in 2025	US$ 58150 million
Forecasted market size in 2032	US$ 121030 million
CAGR	11.2%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	PD-1 Inhibitors PD-L1 Inhibitors
Segment by Product Name	Pembrolizumab Nivolumab Cemiplimab Toripalimab Sintilimab Tislelizumab Camrelizumab Penpulimab Retifanlimab Zimberelimab Atezolizumab Durvalumab Avelumab Envafolimab Adebrelimab
Segment by Dosage Strength	100 mg / Vial 200 mg / Vial 240 mg / Vial 300 mg / Vial
by Application	Squamous Cell Skin Cancer Non-small Cell Lung Cancer Melanoma Gastric Cancer Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Bristol Myers Squibb, Merck, Regeneron Pharmaceuticals, Roche, Pfizer, AstraZeneca, Hengrui Pharmaceuticals, Junshi Biosciences, Innovent
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Product Name, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for PD-1/PD-L1 Checkpoint Inhibitors manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines PD-1/PD-L1 Checkpoint Inhibitors sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is PD-1/PD-L1 Checkpoint Inhibitors Market growing?

Ans: The PD-1/PD-L1 Checkpoint Inhibitors Market witnessing a CAGR of 11.2% during the forecast period 2026-2032.

What is the PD-1/PD-L1 Checkpoint Inhibitors Market size in 2032?

Ans: The PD-1/PD-L1 Checkpoint Inhibitors Market size in 2032 will be US$ 121030 million.

Who are the main players in the PD-1/PD-L1 Checkpoint Inhibitors Market report?

Ans: The main players in the PD-1/PD-L1 Checkpoint Inhibitors Market are Bristol Myers Squibb, Merck, Regeneron Pharmaceuticals, Roche, Pfizer, AstraZeneca, Hengrui Pharmaceuticals, Junshi Biosciences, Innovent

What are the Application segmentation covered in the PD-1/PD-L1 Checkpoint Inhibitors Market report?

Ans: The Applications covered in the PD-1/PD-L1 Checkpoint Inhibitors Market report are Squamous Cell Skin Cancer, Non-small Cell Lung Cancer, Melanoma, Gastric Cancer, Other

What are the Type segmentation covered in the PD-1/PD-L1 Checkpoint Inhibitors Market report?

Ans: The Types covered in the PD-1/PD-L1 Checkpoint Inhibitors Market report are PD-1 Inhibitors, PD-L1 Inhibitors

1 PD-1/PD-L1 Checkpoint Inhibitors Market Overview

1.1 Product Definition

1.2 PD-1/PD-L1 Checkpoint Inhibitors by Type

1.2.1 Global PD-1/PD-L1 Checkpoint Inhibitors Market Value by Type: 2025 vs 2032

1.2.2 PD-1 Inhibitors

1.2.3 PD-L1 Inhibitors

1.3 PD-1/PD-L1 Checkpoint Inhibitors by Product Name

1.3.1 Global PD-1/PD-L1 Checkpoint Inhibitors Market Value by Product Name: 2025 vs 2032

1.3.2 Pembrolizumab

1.3.3 Nivolumab

1.3.4 Cemiplimab

1.3.5 Toripalimab

1.3.6 Sintilimab

1.3.7 Tislelizumab

1.3.8 Camrelizumab

1.3.9 Penpulimab

1.3.10 Retifanlimab

1.4 PD-1/PD-L1 Checkpoint Inhibitors by Dosage Strength

1.4.1 Global PD-1/PD-L1 Checkpoint Inhibitors Market Value by Dosage Strength: 2025 vs 2032

1.4.2 100 mg / Vial

1.4.3 200 mg / Vial

1.4.4 240 mg / Vial

1.4.5 300 mg / Vial

1.5 PD-1/PD-L1 Checkpoint Inhibitors by Application

1.5.1 Global PD-1/PD-L1 Checkpoint Inhibitors Market Value by Application: 2025 vs 2032

1.5.2 Squamous Cell Skin Cancer

1.5.3 Non-small Cell Lung Cancer

1.5.4 Melanoma

1.5.5 Gastric Cancer

1.5.6 Other

1.6 Global PD-1/PD-L1 Checkpoint Inhibitors Market Size Estimates and Forecasts

1.6.1 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue 2021–2032

1.6.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales 2021–2032

1.6.3 Global PD-1/PD-L1 Checkpoint Inhibitors Market Average Price (2021–2032)

1.7 Assumptions and Limitations

2 PD-1/PD-L1 Checkpoint Inhibitors Market Competition by Manufacturers

2.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Manufacturers (2021–2026)

2.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Manufacturers (2021–2026)

2.3 Global PD-1/PD-L1 Checkpoint Inhibitors Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of PD-1/PD-L1 Checkpoint Inhibitors, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of PD-1/PD-L1 Checkpoint Inhibitors, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of PD-1/PD-L1 Checkpoint Inhibitors, Product Types and Applications

2.7 Global Key Manufacturers of PD-1/PD-L1 Checkpoint Inhibitors, Date of Entry into the Industry

2.8 Global PD-1/PD-L1 Checkpoint Inhibitors Market Competitive Situation and Trends

2.8.1 Global PD-1/PD-L1 Checkpoint Inhibitors Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global PD-1/PD-L1 Checkpoint Inhibitors Players Market Share by Revenue

2.8.3 Global PD-1/PD-L1 Checkpoint Inhibitors Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global PD-1/PD-L1 Checkpoint Inhibitors Market Scenario by Region

3.1 Global PD-1/PD-L1 Checkpoint Inhibitors Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region: 2021–2032

3.2.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region: 2021–2026

3.2.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region: 2027–2032

3.3 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region: 2021–2032

3.3.1 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region: 2021–2026

3.3.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region: 2027–2032

3.4 North America PD-1/PD-L1 Checkpoint Inhibitors Market Facts & Figures by Country

3.4.1 North America PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021–2032)

3.4.3 North America PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2021–2032)

3.4.4 United States

3.4.5 Canada

3.5 Europe PD-1/PD-L1 Checkpoint Inhibitors Market Facts & Figures by Country

3.5.1 Europe PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021–2032)

3.5.3 Europe PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Market Facts & Figures by Region

3.6.1 Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales by Region (2021–2032)

3.6.3 Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America PD-1/PD-L1 Checkpoint Inhibitors Market Facts & Figures by Country

3.7.1 Latin America PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021–2032)

3.7.3 Latin America PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Market Facts & Figures by Country

3.8.1 Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021–2032)

3.8.3 Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2021–2032)

4.1.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2021–2026)

4.1.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2027–2032)

4.1.3 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Type (2021–2032)

4.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Type (2021–2032)

4.2.1 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Type (2021–2026)

4.2.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Type (2027–2032)

4.2.3 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Type (2021–2032)

4.3 Global PD-1/PD-L1 Checkpoint Inhibitors Price by Type (2021–2032)

5 Segment by Application

5.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2021–2032)

5.1.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2021–2026)

5.1.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2027–2032)

5.1.3 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Application (2021–2032)

5.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Application (2021–2032)

5.2.1 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Application (2021–2026)

5.2.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Application (2027–2032)

5.2.3 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Application (2021–2032)

5.3 Global PD-1/PD-L1 Checkpoint Inhibitors Price by Application (2021–2032)

6 Key Companies Profiled

6.1 Bristol Myers Squibb

6.1.1 Bristol Myers Squibb Company Information

6.1.2 Bristol Myers Squibb Description and Business Overview

6.1.3 Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio

6.1.5 Bristol Myers Squibb Recent Developments/Updates

6.2 Merck

6.2.1 Merck Company Information

6.2.2 Merck Description and Business Overview

6.2.3 Merck PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 Merck PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio

6.2.5 Merck Recent Developments/Updates

6.3 Regeneron Pharmaceuticals

6.3.1 Regeneron Pharmaceuticals Company Information

6.3.2 Regeneron Pharmaceuticals Description and Business Overview

6.3.3 Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio

6.3.5 Regeneron Pharmaceuticals Recent Developments/Updates

6.4 Roche

6.4.1 Roche Company Information

6.4.2 Roche Description and Business Overview

6.4.3 Roche PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue, and Gross Margin (2021–2026)

6.4.4 Roche PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio

6.4.5 Roche Recent Developments/Updates

6.5 Pfizer

6.5.1 Pfizer Company Information

6.5.2 Pfizer Description and Business Overview

6.5.3 Pfizer PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue, and Gross Margin (2021–2026)

6.5.4 Pfizer PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio

6.5.5 Pfizer Recent Developments/Updates

6.6 AstraZeneca

6.6.1 AstraZeneca Company Information

6.6.2 AstraZeneca Description and Business Overview

6.6.3 AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue, and Gross Margin (2021–2026)

6.6.4 AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio

6.6.5 AstraZeneca Recent Developments/Updates

6.7 Hengrui Pharmaceuticals

6.7.1 Hengrui Pharmaceuticals Company Information

6.7.2 Hengrui Pharmaceuticals Description and Business Overview

6.7.3 Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue, and Gross Margin (2021–2026)

6.7.4 Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio

6.7.5 Hengrui Pharmaceuticals Recent Developments/Updates

6.8 Junshi Biosciences

6.8.1 Junshi Biosciences Company Information

6.8.2 Junshi Biosciences Description and Business Overview

6.8.3 Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue, and Gross Margin (2021–2026)

6.8.4 Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio

6.8.5 Junshi Biosciences Recent Developments/Updates

6.9 Innovent

6.9.1 Innovent Company Information

6.9.2 Innovent Description and Business Overview

6.9.3 Innovent PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue, and Gross Margin (2021–2026)

6.9.4 Innovent PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio

6.9.5 Innovent Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 PD-1/PD-L1 Checkpoint Inhibitors Industry Chain Analysis

7.2 PD-1/PD-L1 Checkpoint Inhibitors Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 PD-1/PD-L1 Checkpoint Inhibitors Production Mode & Process Analysis

7.4 PD-1/PD-L1 Checkpoint Inhibitors Sales and Marketing

7.4.1 PD-1/PD-L1 Checkpoint Inhibitors Sales Channels

7.4.2 PD-1/PD-L1 Checkpoint Inhibitors Distributors

7.5 PD-1/PD-L1 Checkpoint Inhibitors Customer Analysis

8 PD-1/PD-L1 Checkpoint Inhibitors Market Dynamics

8.1 PD-1/PD-L1 Checkpoint Inhibitors Industry Trends

8.2 PD-1/PD-L1 Checkpoint Inhibitors Market Drivers

8.3 PD-1/PD-L1 Checkpoint Inhibitors Market Challenges

8.4 PD-1/PD-L1 Checkpoint Inhibitors Market Restraints

8.5 Impact of U.S. Tariffs

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Bristol–Myers Squibb

Merck

Regeneron Pharmaceuticals

Roche

Pfizer Inc

Astrazeneca plc

Hengrui Pharmaceuticals

Junshi Biosciences

Innovent

List of Tables

Table 1. Global PD-1/PD-L1 Checkpoint Inhibitors Market Value by Type (US$ Million), 2025 vs 2032

Table 2. Global PD-1/PD-L1 Checkpoint Inhibitors Market Value by Product Name (US$ Million), 2025 vs 2032

Table 3. Global PD-1/PD-L1 Checkpoint Inhibitors Market Value by Dosage Strength (US$ Million), 2025 vs 2032

Table 4. Global PD-1/PD-L1 Checkpoint Inhibitors Market Value by Application (US$ Million), 2025 vs 2032

Table 5. Global PD-1/PD-L1 Checkpoint Inhibitors Market Competitive Situation by Manufacturers in 2025

Table 6. Global PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units) of Key Manufacturers (2021–2026)

Table 7. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Manufacturers (2021–2026)

Table 8. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue (US$ Million) by Manufacturers (2021–2026)

Table 9. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Share by Manufacturers (2021–2026)

Table 10. Global Market PD-1/PD-L1 Checkpoint Inhibitors Average Price (US$/Unit) of Key Manufacturers (2021–2026)

Table 11. Global Key Players of PD-1/PD-L1 Checkpoint Inhibitors, Industry Ranking, 2023 vs 2024 vs 2025

Table 12. Global Key Manufacturers of PD-1/PD-L1 Checkpoint Inhibitors, Manufacturing Sites and Headquarters

Table 13. Global Key Manufacturers of PD-1/PD-L1 Checkpoint Inhibitors, Product Types and Applications

Table 14. Global Key Manufacturers of PD-1/PD-L1 Checkpoint Inhibitors, Date of Entry into the Industry

Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 16. Global PD-1/PD-L1 Checkpoint Inhibitors Companies by Tier (Tier 1, Tier 2, Tier 3), based on PD-1/PD-L1 Checkpoint Inhibitors Revenue, 2025

Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 18. Global PD-1/PD-L1 Checkpoint Inhibitors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 19. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region (K Units), 2021–2026

Table 20. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Region (2021–2026)

Table 21. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region (K Units), 2027–2032

Table 22. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Region (2027–2032)

Table 23. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region (US$ Million), 2021–2026

Table 24. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Region (2021–2026)

Table 25. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region (US$ Million), 2027–2032

Table 26. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Region (2027–2032)

Table 27. North America PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 28. North America PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (K Units), 2021–2026

Table 29. North America PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (K Units), 2027–2032

Table 30. North America PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (US$ Million), 2021–2026

Table 31. North America PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (US$ Million), 2027–2032

Table 32. Europe PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 33. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (K Units), 2021–2026

Table 34. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (K Units), 2027–2032

Table 35. Europe PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (US$ Million), 2021–2026

Table 36. Europe PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (US$ Million), 2027–2032

Table 37. Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 38. Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales by Region (K Units), 2021–2026

Table 39. Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales by Region (K Units), 2027–2032

Table 40. Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region (US$ Million), 2021–2026

Table 41. Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region (US$ Million), 2027–2032

Table 42. Latin America PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 43. Latin America PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (K Units), 2021–2026

Table 44. Latin America PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (K Units), 2027–2032

Table 45. Latin America PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (US$ Million), 2021–2026

Table 46. Latin America PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (US$ Million), 2027–2032

Table 47. Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 48. Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (K Units), 2021–2026

Table 49. Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (K Units), 2027–2032

Table 50. Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (US$ Million), 2021–2026

Table 51. Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (US$ Million), 2027–2032

Table 52. Global PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units) by Type (2021–2026)

Table 53. Global PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units) by Type (2027–2032)

Table 54. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Type (2021–2026)

Table 55. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Type (2027–2032)

Table 56. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue (US$ Million) by Type (2021–2026)

Table 57. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue (US$ Million) by Type (2027–2032)

Table 58. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Type (2021–2026)

Table 59. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Type (2027–2032)

Table 60. Global PD-1/PD-L1 Checkpoint Inhibitors Price (US$/Unit) by Type (2021–2026)

Table 61. Global PD-1/PD-L1 Checkpoint Inhibitors Price (US$/Unit) by Type (2027–2032)

Table 62. Global PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units) by Application (2021–2026)

Table 63. Global PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units) by Application (2027–2032)

Table 64. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Application (2021–2026)

Table 65. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Application (2027–2032)

Table 66. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue (US$ Million) by Application (2021–2026)

Table 67. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue (US$ Million) by Application (2027–2032)

Table 68. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Application (2021–2026)

Table 69. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Application (2027–2032)

Table 70. Global PD-1/PD-L1 Checkpoint Inhibitors Price (US$/Unit) by Application (2021–2026)

Table 71. Global PD-1/PD-L1 Checkpoint Inhibitors Price (US$/Unit) by Application (2027–2032)

Table 72. Bristol Myers Squibb Company Information

Table 73. Bristol Myers Squibb Description and Business Overview

Table 74. Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 75. Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Product

Table 76. Bristol Myers Squibb Recent Developments/Updates

Table 77. Merck Company Information

Table 78. Merck Description and Business Overview

Table 79. Merck PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 80. Merck PD-1/PD-L1 Checkpoint Inhibitors Product

Table 81. Merck Recent Developments/Updates

Table 82. Regeneron Pharmaceuticals Company Information

Table 83. Regeneron Pharmaceuticals Description and Business Overview

Table 84. Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 85. Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product

Table 86. Regeneron Pharmaceuticals Recent Developments/Updates

Table 87. Roche Company Information

Table 88. Roche Description and Business Overview

Table 89. Roche PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 90. Roche PD-1/PD-L1 Checkpoint Inhibitors Product

Table 91. Roche Recent Developments/Updates

Table 92. Pfizer Company Information

Table 93. Pfizer Description and Business Overview

Table 94. Pfizer PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 95. Pfizer PD-1/PD-L1 Checkpoint Inhibitors Product

Table 96. Pfizer Recent Developments/Updates

Table 97. AstraZeneca Company Information

Table 98. AstraZeneca Description and Business Overview

Table 99. AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 100. AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Product

Table 101. AstraZeneca Recent Developments/Updates

Table 102. Hengrui Pharmaceuticals Company Information

Table 103. Hengrui Pharmaceuticals Description and Business Overview

Table 104. Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 105. Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product

Table 106. Hengrui Pharmaceuticals Recent Developments/Updates

Table 107. Junshi Biosciences Company Information

Table 108. Junshi Biosciences Description and Business Overview

Table 109. Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 110. Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Product

Table 111. Junshi Biosciences Recent Developments/Updates

Table 112. Innovent Company Information

Table 113. Innovent Description and Business Overview

Table 114. Innovent PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 115. Innovent PD-1/PD-L1 Checkpoint Inhibitors Product

Table 116. Innovent Recent Developments/Updates

Table 117. Key Raw Materials Lists

Table 118. Raw Materials Key Suppliers Lists

Table 119. PD-1/PD-L1 Checkpoint Inhibitors Distributors List

Table 120. PD-1/PD-L1 Checkpoint Inhibitors Customers List

Table 121. PD-1/PD-L1 Checkpoint Inhibitors Market Trends

Table 122. PD-1/PD-L1 Checkpoint Inhibitors Market Drivers

Table 123. PD-1/PD-L1 Checkpoint Inhibitors Market Challenges

Table 124. PD-1/PD-L1 Checkpoint Inhibitors Market Restraints

Table 125. Research Programs/Design for This Report

Table 126. Key Data Information from Secondary Sources

Table 127. Key Data Information from Primary Sources

Table 128. Authors List of This Report

List of Figures

Figure 1. Product Picture of PD-1/PD-L1 Checkpoint Inhibitors

Figure 2. Global PD-1/PD-L1 Checkpoint Inhibitors Market Value by Type (US$ Million), 2021–2032

Figure 3. Global PD-1/PD-L1 Checkpoint Inhibitors Market Share by Type: 2025 & 2032

Figure 4. PD-1 Inhibitors Product Picture

Figure 5. PD-L1 Inhibitors Product Picture

Figure 6. Global PD-1/PD-L1 Checkpoint Inhibitors Market Value by Product Name (US$ Million), 2021–2032

Figure 7. Global PD-1/PD-L1 Checkpoint Inhibitors Market Share by Product Name: 2025 vs 2032

Figure 8. Pembrolizumab Product Picture

Figure 9. Nivolumab Product Picture

Figure 10. Cemiplimab Product Picture

Figure 11. Toripalimab Product Picture

Figure 12. Sintilimab Product Picture

Figure 13. Tislelizumab Product Picture

Figure 14. Camrelizumab Product Picture

Figure 15. Penpulimab Product Picture

Figure 16. Retifanlimab Product Picture

Figure 17. Global PD-1/PD-L1 Checkpoint Inhibitors Market Value by Dosage Strength (US$ Million), 2021–2032

Figure 18. Global PD-1/PD-L1 Checkpoint Inhibitors Market Share by Dosage Strength: 2025 vs 2032

Figure 19. 100 mg / Vial Product Picture

Figure 20. 200 mg / Vial Product Picture

Figure 21. 240 mg / Vial Product Picture

Figure 22. 300 mg / Vial Product Picture

Figure 23. Global PD-1/PD-L1 Checkpoint Inhibitors Market Value by Application (US$ Million), 2021–2032

Figure 24. Global PD-1/PD-L1 Checkpoint Inhibitors Market Share by Application: 2025 & 2032

Figure 25. Squamous Cell Skin Cancer

Figure 26. Non-small Cell Lung Cancer

Figure 27. Melanoma

Figure 28. Gastric Cancer

Figure 29. Other

Figure 30. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 31. Global PD-1/PD-L1 Checkpoint Inhibitors Market Size (US$ Million), 2021–2032

Figure 32. Global PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), 2021–2032

Figure 33. Global PD-1/PD-L1 Checkpoint Inhibitors Average Price (US$/Unit), 2021–2032

Figure 34. PD-1/PD-L1 Checkpoint Inhibitors Report Years Considered

Figure 35. PD-1/PD-L1 Checkpoint Inhibitors Sales Share by Manufacturers in 2025

Figure 36. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Share by Manufacturers in 2025

Figure 37. Top 5 and Top 10 Global PD-1/PD-L1 Checkpoint Inhibitors Players: Market Share by Revenue in PD-1/PD-L1 Checkpoint Inhibitors in 2025

Figure 38. PD-1/PD-L1 Checkpoint Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 39. Global PD-1/PD-L1 Checkpoint Inhibitors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Figure 40. North America PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Country (2021–2032)

Figure 41. North America PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Country (2021–2032)

Figure 42. United States PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (US$ Million), 2021–2032

Figure 43. Canada PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (US$ Million), 2021–2032

Figure 44. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Country (2021–2032)

Figure 45. Europe PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Country (2021–2032)

Figure 46. Germany PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (US$ Million), 2021–2032

Figure 47. France PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (US$ Million), 2021–2032

Figure 48. U.K. PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (US$ Million), 2021–2032

Figure 49. Italy PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (US$ Million), 2021–2032

Figure 50. Russia PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (US$ Million), 2021–2032

Figure 51. Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Region (2021–2032)

Figure 52. Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Region (2021–2032)

Figure 53. China PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (US$ Million), 2021–2032

Figure 54. Japan PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (US$ Million), 2021–2032

Figure 55. South Korea PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (US$ Million), 2021–2032

Figure 56. India PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (US$ Million), 2021–2032

Figure 57. Australia PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (US$ Million), 2021–2032

Figure 58. China Taiwan PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (US$ Million), 2021–2032

Figure 59. Southeast Asia PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (US$ Million), 2021–2032

Figure 60. Latin America PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Country (2021–2032)

Figure 61. Latin America PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Country (2021–2032)

Figure 62. Mexico PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (US$ Million), 2021–2032

Figure 63. Brazil PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (US$ Million), 2021–2032

Figure 64. Argentina PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (US$ Million), 2021–2032

Figure 65. Colombia PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (US$ Million), 2021–2032

Figure 66. Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Country (2021–2032)

Figure 67. Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Country (2021–2032)

Figure 68. Turkey PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (US$ Million), 2021–2032

Figure 69. Saudi Arabia PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (US$ Million), 2021–2032

Figure 70. UAE PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (US$ Million), 2021–2032

Figure 71. Global Sales Market Share of PD-1/PD-L1 Checkpoint Inhibitors by Type (2021–2032)

Figure 72. Global Revenue Market Share of PD-1/PD-L1 Checkpoint Inhibitors by Type (2021–2032)

Figure 73. Global PD-1/PD-L1 Checkpoint Inhibitors Price (US$/Unit) by Type (2021–2032)

Figure 74. Global Sales Market Share of PD-1/PD-L1 Checkpoint Inhibitors by Application (2021–2032)

Figure 75. Global Revenue Market Share of PD-1/PD-L1 Checkpoint Inhibitors by Application (2021–2032)

Figure 76. Global PD-1/PD-L1 Checkpoint Inhibitors Price (US$/Unit) by Application (2021–2032)

Figure 77. PD-1/PD-L1 Checkpoint Inhibitors Value Chain

Figure 78. Channels of Distribution (Direct Vs Distribution)

Figure 79. Bottom-up and Top-down Approaches for This Report

Figure 80. Data Triangulation

Figure 81. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Immune Checkpoint Inhibitors for Cancer Market Research Report 2024

Pd 1 and Pd L1 Inhibitors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Checkpoint Inhibitors for Treating Cancer Market Insights Forecast to 2030

PD L1 Inhibitors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

PD 1 and PD L1 Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global PD 1 Drugs for the Treatment of Cervical Cancer Market Research Report 2025

Global PD L1 Biomarker Testing Platform Market Insights Forecast to 2030

Global ICIs for Cervical Cancer Market Research Report 2025

Global Immune Checkpoint Proteins Market Research Report 2024

Global PD 1 and PD L1 Monoclonal Antibody Market Research Report 2025

Global Anti PD 1 Antibody Market Insights Forecast to 2030

Global CTLA 4 Inhibitors for Cervical Cancer Market Research Report 2024

Global PD L1 Biomarker Testing Market Insights Forecast to 2030

Global PD 1 Inhibitor Market Research Report 2024

Global PD L1 and PIK3CA Testing Market Research Report 2024

Global PD 1 and PD L1 Immunotherapy Market Insights Forecast to 2030

Global Combination Therapies for Melanoma Market Research Report 2024

Global PD 1 and PD L1 Antibody Market Insights Forecast to 2030

Global Cancer Immunotherapies Market Insights Forecast to 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions